A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.
Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.
Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development.
Augmented intelligence is strategically valuable because it strengthens both the scientific and financial case for every decision.
One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.
Editor's Picks
